You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
AstraZeneca
McKesson
Harvard Business School
Medtronic

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 10,233,503

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,233,503
Title:Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
Abstract: The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.
Inventor(s): Badosa; Manel Esteller (Barcelona, ES)
Assignee: FUNDACIO INSTITUT D\'INVESTIGACIO BIOM DICA DE BELLVITGE (IDIBELL) (Barcelona, ES)
Application Number:14/402,736
Patent Claims:see list of patent claims

Details for Patent 10,233,503

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial FUNDACIO INSTITUT D\'INVESTIGACIO BIOM DICA DE BELLVITGE (IDIBELL) (Barcelona, ES) 2039-03-23 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial FUNDACIO INSTITUT D\'INVESTIGACIO BIOM DICA DE BELLVITGE (IDIBELL) (Barcelona, ES) 2039-03-23 RX Orphan search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial FUNDACIO INSTITUT D\'INVESTIGACIO BIOM DICA DE BELLVITGE (IDIBELL) (Barcelona, ES) 2039-03-23 RX search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial FUNDACIO INSTITUT D\'INVESTIGACIO BIOM DICA DE BELLVITGE (IDIBELL) (Barcelona, ES) 2039-03-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Johnson and Johnson
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.